{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:58Z","timestamp":1788239818473,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The abscopal effect is a systemic anti-tumor immune response induced by local radiotherapy (RT), resulting in regression of distant, non-irradiated tumors. Although ablative RT is more effective than conventionally fractionated RT in inducing this response, the underlying mechanisms remain incompletely understood, and strategies to enhance the abscopal effect following conventional RT are still needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We compared the immunological and therapeutic effects of ablative RT (15 Gy in a single fraction) and non-ablative RT (4 Gy in 10 fractions; biologically equivalent to 40 Gy) using murine breast cancer models. Tumor growth, immune cell infiltration, dendritic cell activation, cytokine expression and type I interferon signaling were analyzed. Functional studies were performed using CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell depletion, IFNAR1 blockade, recombinant IFN-\u03b2 administration and anti-PD-L1 treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ablative radiation induced abscopal response characterized by significant suppression of distant tumor growth, whereas non-ablative RT failed to elicit this effect despite comparable local tumor control. The abscopal response depended on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and was associated with increased infiltration of activated CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells into distant tumors. Ablative RT promoted the recruitment and activation of CD11c\n                      <jats:sup>+<\/jats:sup>\n                      dendritic cells, particularly CD103\n                      <jats:sub>+<\/jats:sub>\n                      cells, in both tumors and draining lymph nodes. The cytokine qPCR array suggested that increased signaling of type I IFN and the mRNA and protein levels of type I IFN, specifically IFN-\u03b2 significantly upregulated in tumor tissues irradiated with ablative radiation. Blocking IFNAR1 abolished the abscopal response, whereas administration of recombinant IFN-\u03b2 restored the ability of sub-ablative RT to induce systemic anti-tumor immunity. Furthermore, combining recombinant IFN-\u03b2 with anti-PD-L1 therapy significantly enhanced the therapeutic efficacy of sub-ablative RT in murine breast, colon, and lung cancer models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify IFN-\u03b2 as a critical mediator of RT-induced abscopal immunity and demonstrate that IFN-\u03b2 supplementation can overcome the limited systemic efficacy of conventional fractionated RT. These results provide a rationale for combining IFN-\u03b2 with radiotherapy and immune checkpoint blockade to enhance systemic anti-tumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1925859","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:59Z","timestamp":1788236819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Augmenting interferon-\u03b2 and anti-PD-L1 antibody bolsters non-ablative radiotherapy to leverage potent abscopal effect in metastatic cancers"],"prefix":"10.3389","volume":"17","author":[{"given":"Jin Hee","family":"Park","sequence":"first","affiliation":[{"name":"Department of Microbiology, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine","place":["Changwon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Microbiology, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Jung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Busan Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-tae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Busan Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun Do","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Ilsan Paik Hospital, College of Medicine, Inje University","place":["Goyang, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Busan Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IL-Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Haeundae Paik Hospital, College of Medicine, Inje University","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SaeGwang","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Microbiology, College of Medicine, Inje University","place":["Busan, Republic of Korea"]},{"name":"NexThera Co., Ltd.","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21324","article-title":"The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines","volume":"104","author":"Delaney","year":"2005","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708810","article-title":"Local destruction of tumors and systemic immune effects","volume":"11","author":"Tranberg","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: Present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12609-017-0234-y","article-title":"The abscopal effect of radiation therapy: What is it and how can we use it in breast cancer","volume":"9","author":"Hu","year":"2017","journal-title":"Curr Breast Cancer Rep"},{"key":"B5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2307\/3572600","article-title":"Radiobiology of human cancer radiotherapy","author":"Andrews","year":"1978"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.2494.1146","article-title":"On the analogy between spontaneous recoveries from cancer and the specific immunity induced by x ray irradiations of the lymphatic glands involved","volume":"2","author":"McCulloch","year":"1908","journal-title":"Br Med J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2017.06.001","article-title":"Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports","volume":"2","author":"Ebner","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require cd8+ t cells: Changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5483\/bmbrep.2021.54.1.224","article-title":"The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets","volume":"54","author":"Kim","year":"2021","journal-title":"BMB Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: From mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3818","article-title":"Revisiting stat3 signalling in cancer: New and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.immuni.2018.07.008","article-title":"Non-canonical nf-kappab antagonizes sting sensor-mediated dna sensing in radiotherapy","volume":"49","author":"Hou","year":"2018","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-her2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Park","year":"2010","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4956","article-title":"Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 r172h mutant mice","volume":"6","author":"Goh","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","article-title":"Systematic review of case reports on the abscopal effect","volume":"40","author":"Abuodeh","year":"2016","journal-title":"Curr Probl Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6516","article-title":"Analysis of hospitalization length of stay and total charges for patients with drug abuse comorbidity","volume":"11","author":"Ndanga","year":"2019","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001467","article-title":"Oncology in the digital health age","volume":"10","author":"Yu","year":"2014","journal-title":"J Oncol Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6628","article-title":"Enhancement of adoptive t cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice","volume":"6","author":"Hsu","year":"2015","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-pd-l1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.011","article-title":"Optimizing radiation therapy to boost systemic immune responses in breast cancer: A critical review for breast radiation oncologists","volume":"108","author":"Ho","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5818","article-title":"Exosomes enriched in stemness\/metastatic-related mrnas promote oncogenic potential in breast cancer","volume":"6","author":"Rodriguez","year":"2015","journal-title":"Oncotarget"},{"key":"B27","article-title":"Decrease in radio-sensitivity of the tumor by radiation-induced damage to immuno-related cells","volume":"33","author":"Makidono","year":"1987","journal-title":"Gan No Rinsho"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6528","article-title":"Endovascular approach to severe acute type b aortic dissection","volume":"11","author":"Ternes Rech","year":"2019","journal-title":"Cureus"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.20.02046","article-title":"Time to debunk an urban myth? The \"abscopal effect\" with radiation and anti-pd-1","volume":"39","author":"Seiwert","year":"2021","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-ctla-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nri3845","article-title":"Type i interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1179064418761639","article-title":"The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules","volume":"11","author":"Arnold","year":"2018","journal-title":"Cancer Growth Metastasis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type i interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930601)71:11<3717::aid-cncr2820711140>3.0.co;2-i","article-title":"In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines","volume":"71","author":"Angioli","year":"1993","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2307\/3580145","article-title":"Sensitizing human cervical cancer cells in vitro to ionizing radiation with interferon beta or gamma","volume":"152","author":"Gruninger","year":"1999","journal-title":"Radiat Res"},{"key":"B37","article-title":"Combination interferon-alpha2a and 13-cis-retinoic acid enhances radiosensitization of human Malignant glioma cells in vitro","volume":"5","author":"Malone","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B38","article-title":"Recombinant human interferon alpha-2b enhances the radiosensitivity of small cell lung cancer in vitro","volume":"9","author":"Kardamakis","year":"1989","journal-title":"Anticancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.009","article-title":"Type i interferons as radiosensitisers for pancreatic cancer","volume":"47","author":"Morak","year":"2011","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12935-021-01997-7","article-title":"Ifi35 is involved in the regulation of the radiosensitivity of colorectal cancer cells","volume":"21","author":"Hu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212581","article-title":"Radiotherapy resistance acquisition in glioblastoma. Role of socs1 and socs3","volume":"14","author":"Ventero","year":"2019","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s0360-3016(01)02700-6","article-title":"Combined adjuvant radiation and interferon-alpha 2b therapy in high-risk melanoma patients: The potential for increased radiation toxicity","volume":"52","author":"Hazard","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00008390-200302000-00011","article-title":"Concurrent interferon-alpha and radiation for head and neck melanoma","volume":"13","author":"Nguyen","year":"2003","journal-title":"Melanoma Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102413","article-title":"Structure-function of type i and iii interferons","volume":"86","author":"de Weerd","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2287681","article-title":"An extracellular humanized ifnar immunocompetent mouse model for analyses of human interferon alpha and subtypes","volume":"13","author":"Li","year":"2024","journal-title":"Emerg Microbes Infect"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.12.031","article-title":"Enlightening the immune mechanism of the abscopal effect in a murine hcc model and overcoming the late resistance with anti-pd-l1","volume":"110","author":"Park","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13691-018-0349-7","article-title":"Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: Report of two cases","volume":"8","author":"Matsushita","year":"2019","journal-title":"Int Cancer Conf J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8423","article-title":"Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report","volume":"19","author":"Hori","year":"2020","journal-title":"Exp Ther Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02587-8","article-title":"Deep abscopal response to radiotherapy and anti-pd-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature","volume":"69","author":"Watanabe","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3511","article-title":"Tgfbeta is a master regulator of radiation therapy-induced antitumor immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-026-02570-9","article-title":"Timing matters: How mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review","author":"Cattaneo","year":"2026","journal-title":"Strahlenther Onkol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: Mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3142","article-title":"Suppression of type I Ifn signaling in tumors mediates resistance to anti-Pd-1 treatment that can be overcome by radiotherapy","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1022542","article-title":"Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer","volume":"12","author":"Jungles","year":"2022","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:27:01Z","timestamp":1788236821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1925859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1925859"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1925859","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1925859"}}